Lotus Pharmaceuticals, Inc.
Simbolis: LTUS
PNK
0.00401
USDRinkos kaina šiandien
-651.6106
P/E santykis
-3.8330
PEG koeficientas
0.11M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Lotus Pharmaceuticals, Inc. (LTUS) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 2.7 | 2.7 | 2.9 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -32.8 | -32.8 | -32.8 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -2.7 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 30 | 32.7 | 29.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.net-debt | 0 | 0.1 | 0.1 | 0.1 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 0 | 0 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | 0 | 0 | 0 | 0 |
Dažnai užduodami klausimai
Kas yra Lotus Pharmaceuticals, Inc. (LTUS) bendras turtas?
Lotus Pharmaceuticals, Inc. (LTUS) bendras turtas yra 5681.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.000.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra Lotus Pharmaceuticals, Inc. (LTUS) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -18812.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 116683.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 18812.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.